1.Castro, A.G. et al. (1999) J. Immunol. 163:5860. 2.Cocks, B.G. et al. (1995) Nature 376:260. 3.Wang, N. et al. (2004) J. Exp. Med. 199:1255. 4.Hahm, B. et al. (2004) Virology 323:292. 5.Nanda, N. et al. (2005) Blood 106:3028. 6.Kiel, M.J. et al. (2005) Cell 121:1109.
The type I transmembrane glycoprotein Signaling Lymphocytic Activation Molecule (SLAM), also known as CD150, is the prototypic member of the SLAM subgroup of the CD2 protein family. Alternate splicing generates an isoform with a substituted cytoplasmic domain. SLAM is expressed on T cells, B cells, thymocytes, macrophages, dendritic cells, platelets, and hematopoietic stem cells. It is up‑regulated on activated B cells and CD4+ and CD8+ T cells, although it is down‑regulated on Th2 polarized cells. SLAM interacts homophilically with low affinity, and this interaction induces a Th0/Th1 response characterized by clonal expansion, production of IFN-gamma, and increased cytolytic activity of CD8+ T cells. SLAM ligation also promotes B cell activation, allergen-induced eosinophil and mast cell activation, NKT cell development, and the microbicidal response of macrophages to Gram negative bacteria. In humans, SLAM functions as a cellular entry receptor for measles virus.
1μg (R: reducing condition, N: non-reducing condition).
您现在的位置：